July 27, 2021

Axsome Clinical Trials is assessing the efficacy and safety of AXS-05 to treat agitation in Alzheimer’s

This trial will assess the efficacy and safety of AXS-05, an investigational drug combining FDA-approved bupropion and dextromethorphan, to treat agitation in older adults with Alzheimer’s disease.

Researchers are exploring this treatment for Alzheimer’s-related agitation, characterized by emotional distress, aggressive behaviors, disruptive irritability, and disinhibition. This study will compare the effectiveness of AXS-05 to that of bupropion alone or a placebo. Participants will take a pill of either the study drug or a placebo once daily by mouth for 5 weeks.

Find out whether you or your loved one is eligible for the trial.

Leave a Reply

Your email address will not be published. Required fields are marked *

Hey there!
Would you like to be notified when we publish new content?

You have successfully subscribed

There was an error while trying to send your request. Please try again.

Hopeful Trials & News will use the information you provide on this form to be in touch with you and to provide updates and marketing.